Abstract
Greystone Research Associates is pleased to announce the publication of a new
market study. Inhaled Drug Delivery: Devices, Indications, Therapeutics,
Markets and Forecasts is a comprehensive evaluation and analysis of the
technology, products and participants providing the driving force behind this
evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery
developers, device designers, healthcare marketers, and supply chain
participants with a detailed understanding of the economics, technologies,
disease segments, and commercial opportunities for inhaled drug delivery.
Provider organization business managers, healthcare administrators and
investors will also benefit from this study.
User-friendly Administration for a Diverse and Growing Therapeutic Need
Advances in drug formulation and inhalation device design are creating new
opportunities for inhaled drug delivery as an alternative to oral and
parenteral delivery methods. Much of the interest in pulmonary delivery of
systemic drug therapies is focused on chronic diseases and refractory
conditions - aliments that require frequent drug administration for a
protracted period of time.
The role of device design and development in defining and driving emerging
opportunities in this sector cannot be overstated. Nebulizers, metered dose
inhalers (MDIs), and dry powder inhalers (DPIs) have each found a niche in the
quest for optimal treatment and convenient use. While nebulizers have evolved
relatively independently of the drug formulations they deliver, the current
generation of MDIs and DPIs have been developed or tailored for the specific
pharmaceutical being delivered, resulting in improved performance.
Report Value Matrix
Highlights
- Analyzes and evaluates inhaled drugs currently in development and assesses
the market potential for existing and probable future products
- Examines inhalation device technology for commercial and development-stage
devices, and evaluates product technology issues and evolving market factors
- Provides detailed assessments of targeted disease segments, forecast
growth and market potential, and therapeutic options
- Forecasts the impact of new and emerging inhaled drug therapeutics on
healthcare markets and prescribing decisions to 2016
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations.
Forecasts and projections of market demand and future market activity are
derived using standard modeling and statistical techniques.
About Greystone Associates
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Table of Contents
- Inhaled Drug Market Dynamics
- Therapeutic Targets
- Demographics and Growth
- Competing Technologies
- Market Drivers
- Factors Limiting Growth
- Inhalation Technology & Product
- Drug Formulations
- Formulation Technologies
- Excipients and Release Profiles
- Inhalation Device Design Factors
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
- Performance Factors
- Bioavailability
- Dose Reproducibility
- Active Compound Stability
- Combination Drug Inhalers
- Testing and Packaging
- Emerging Device Technologies
- Inhalation Devices - Device
- Assessments and Product Strategies
- Dry Powder inhalers
- Commercial Devices
- Development-stage DPI Devices
- Metered Dose Inhalers
- Nebulizers
- Compressed Air Nebulizers
- Ultrasonic Nebulizers
- Advanced Technology Nebulizers
- Inhaled Drugs - Therapeutic Segment
- Upper Respiratory Indications
- Asthma/COPD
- Allergic Rhinitis
- Systemic Drug Delivery
- Anaphylaxis
- Bioterror
- Cardiovascular Medicine
- Diabetes
- Hereditary Diseases
- Immunology
- Infectious Diseases
- Osteoporosis
- Neurology
- Oncology
- Pain Management
- Sexual Health
- Market Factors
- Device Packaging
- Regulatory Issues
- Patient Compliance
- The Role of CMOs/CSOs
- Healthcare Economics
- Market Sector Company Profiles
Inhaled Drug Delivery: Devices, Indications, Therapeutics, Markets and Forecasts published by Greystone Research Associates in January 16, 2012. This report price starts from US $ 3850.
The contents of this page may be different from the latest version. Please contact us for details.
